Latest & greatest articles for tuberculosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for tuberculosis

81. The impacts of social support on the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis

The impacts of social support on the treatment outcomes of drug-resistant tuberculosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

82. Prevalence rates and factors influencing adherence to anti-tuberculosis treatment in low and middle-income countries (LMICs): a systematic review and meta-analysis

Prevalence rates and factors influencing adherence to anti-tuberculosis treatment in low and middle-income countries (LMICs): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

83. Patients' experiences of tuberculosis treatment using directly observed short-course: a meta aggregation

Patients' experiences of tuberculosis treatment using directly observed short-course: a meta aggregation Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

84. Pulmonary tuberculosis screening by pouched rat: a meta-analysis of sensitivity and specificity

Pulmonary tuberculosis screening by pouched rat: a meta-analysis of sensitivity and specificity Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

85. Poor treatment adherence and associated factors among patients taking anti-tuberculosis drug in Ethiopia: systematic review and meta-analysis

Poor treatment adherence and associated factors among patients taking anti-tuberculosis drug in Ethiopia: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

86. Re-introduction of anti-tuberculosis agents after recovery from drug-induced hepatitis due to first-line anti-TB drugs: a systematic review and meta-analysis

Re-introduction of anti-tuberculosis agents after recovery from drug-induced hepatitis due to first-line anti-TB drugs: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

87. Gender difference in co-morbid depression among tuberculosis patients in high burden countries: systematic review and meta-analysis

Gender difference in co-morbid depression among tuberculosis patients in high burden countries: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

88. Epidemiology tuberculosis among refugee and pastoral community in Ethiopia: a systematic review and meta-analysis

Epidemiology tuberculosis among refugee and pastoral community in Ethiopia: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

89. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. (PubMed)

Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. Early initiation of antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-infected patients who have tuberculosis reduces mortality among patients with low CD4 counts, but it increases the risk of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS).We conducted this randomized, double-blind, placebo-controlled trial to assess whether prophylactic prednisone can safely (...) reduce the incidence of paradoxical tuberculosis-associated IRIS in patients at high risk for the syndrome. We enrolled HIV-infected patients who were initiating ART (and had not previously received ART), had started tuberculosis treatment within 30 days before initiating ART, and had a CD4 count of 100 cells or fewer per microliter. Patients received either prednisone (at a dose of 40 mg per day for 14 days, then 20 mg per day for 14 days) or placebo. The primary end point was the development

2018 NEJM Controlled trial quality: predicted high

90. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study

Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information (...) you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found modest differences between tests in identifying individuals who would go on to develop active tuberculosis, but a two-step approach was the most cost-effective testing option. {{author}} {{($index , , , , , , , , , , , , & . Ibrahim Abubakar 1, * , Ajit Lalvani 2 , Jo Southern 3 , Alice Sitch 4 , Charlotte Jackson 1 , Oluchukwu Onyimadu 5 , Marc Lipman 6 , Jonathan J

2018 NIHR HTA programme

91. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities (PubMed)

Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities Poor medication adherence may increase rates of loss to follow-up, disease relapse and drug resistance for individuals with active tuberculosis (TB). While TB programmes have historically used directly observed therapy (DOT) to address adherence, concerns have been raised about the patient burden, ethical limitations, effectiveness in improving treatment outcomes and long

Full Text available with Trip Pro

2018 BMJ global health

92. Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India (PubMed)

Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India The End TB Strategy envisions a world free of tuberculosis-zero deaths, disease and suffering due to tuberculosis by 2035. This requires reducing the global tuberculosis incidence from >1250 cases per million people to <100 cases per million people within the next two decades. Expanding testing and treatment of tuberculosis infection is critical to achieving this goal. In high-burden countries, like India (...) , the implementation of tuberculosis preventive treatment (TPT) remains a low priority. In this analysis article, we explore potential challenges and solutions of implementing TPT in India. The next chapter in tuberculosis elimination in India will require cost-effective and sustainable interventions aimed at tuberculosis infection. This will require constant innovation, locally driven solutions to address the diverse and dynamic tuberculosis epidemiology and persistent programme monitoring and evaluation. As new

Full Text available with Trip Pro

2018 BMJ global health

93. Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective

Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective Discover Portal Discover Portal Rapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective Published on 9 November 2015 doi: This NIHR funded systematic review and economic evaluation found that three rapid tests for diagnosing drug resistant tuberculosis were highly accurate (...) health risk of tuberculosis. Share your views on the research. Why was this study needed? A 2014 Public Health England report showed that tuberculosis (TB) rates in the UK continue to be among the highest of West European countries. There were 7,892 cases of TB recorded in the UK in 2013, around 12 per 100,000 people. TB that does not respond to two of the standard treatments, called multidrug resistant TB, is becoming more common in the UK. Between 2004 and 2011, the proportion of cases

2018 NIHR Dissemination Centre

94. What constitutes an effective and efficient package of services for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health

What constitutes an effective and efficient package of services for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health Sally Hargreaves | Kieran Rustage | Laura B Nellums | Jaynaide Powis | James Milburn Santino Severoni | Masoud Dara | Soorej J Puthoopparambil | Jon S Friedland HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 56 What constitutes an effective and efficient package of services (...) for the prevention, diagnosis, treatment and care of tuberculosis among refugees and migrants in the WHO European Region? Themed issues on migration and health, VIIIThe Health Evidence Network The Health Evidence Network (HEN) is an information service for public health decision-makers in the WHO European Region, in action since 2003 and initiated and coordinated by the WHO Regional Office for Europe under the umbrella of the European Health Information Initiative (a multipartner network coordinating all health

2018 WHO Health Evidence Network

95. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. (PubMed)

Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. The World Health Organization recommends drug-susceptibility testing of Mycobacterium tuberculosis complex for all patients with tuberculosis to guide treatment decisions and improve outcomes. Whether DNA sequencing can be used to accurately predict profiles of susceptibility to first-line antituberculosis drugs has not been clear.We obtained whole-genome sequences and associated phenotypes of resistance (...) . Among the 4037 phenotypic profiles that were predicted to be pansusceptible, 3952 (97.9%) were correctly predicted.Genotypic predictions of the susceptibility of M. tuberculosis to first-line drugs were found to be correlated with phenotypic susceptibility to these drugs. (Funded by the Bill and Melinda Gates Foundation and others.).

Full Text available with Trip Pro

2018 NEJM

96. Phase 2b Controlled Trial of M72/AS01<sub>E</sub> Vaccine to Prevent Tuberculosis. (PubMed)

Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. A vaccine to interrupt the transmission of tuberculosis is needed.We conducted a randomized, double-blind, placebo-controlled, phase 2b trial of the M72/AS01E tuberculosis vaccine in Kenya, South Africa, and Zambia. Human immunodeficiency virus (HIV)-negative adults 18 to 50 years of age with latent M. tuberculosis infection (by interferon-γ release assay) were randomly assigned (in a 1:1 ratio) to receive two (...) doses of either M72/AS01E or placebo intramuscularly 1 month apart. Most participants had previously received the bacille Calmette-Guérin vaccine. We assessed the safety of M72/AS01E and its efficacy against progression to bacteriologically confirmed active pulmonary tuberculosis disease. Clinical suspicion of tuberculosis was confirmed with sputum by means of a polymerase-chain-reaction test, mycobacterial culture, or both.We report the primary analysis (conducted after a mean of 2.3 years

Full Text available with Trip Pro

2018 NEJM Controlled trial quality: predicted high

97. Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. (PubMed)

Sensitivity and specificity of using trial-of-antibiotics versus sputum mycobacteriology for diagnosis of tuberculosis: protocol for a systematic literature review. Suboptimal diagnostics for pulmonary tuberculosis (PTB) drives use of 'trial-of-antibiotics (non-tuberculosis)' in an attempt to distinguish PTB patients from those with bacterial lower respiratory tract infection (LRTI). The underlying assumption-that patients with LRTI will report 'response' to broad-spectrum antibiotics, while

Full Text available with Trip Pro

2018 Systematic Reviews

98. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. (PubMed)

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.In this individual patient data meta-analysis, we searched MEDLINE, Embase (...) , and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016. We also searched reference lists from all systematic reviews of treatment of multidrug-resistant tuberculosis published since 2009. To be eligible, studies had to report original results, with end of treatment outcomes (treatment completion [success], failure, or relapse) in cohorts of at least 25 adults (aged >18 years). We used anonymised individual patient data

2018 Lancet

99. Handbook on tuberculosis laboratory diagnostic methods in the European Union

Handbook on tuberculosis laboratory diagnostic methods in the European Union TECHNICAL REPORT www.ecdc.europa.eu Handbook on tuberculosis laboratory diagnostic methods in the European Union Updated 2018ECDC TECHNICAL REPORT Handbook on tuberculosis laboratory diagnostic methods in the European Union Updated 2018 ii This report of the European Centre for Disease Prevention and Control (ECDC) was coordinated by Csaba Ködmön with support from Marieke J. van der Werf, Francis Drobniewski (...) ’ in 2016 and further revised and renamed ‘Handbook on tuberculosis laboratory diagnostic methods in the European Union – Updated 2018’ with changes to Chapters 6.7 and 10.4 in 2018 as new scientific evidence became available. Suggested citation: European Centre for Disease Prevention and Control. Handbook on tuberculosis laboratory diagnostic methods in the European Union – Updated 2018. Stockholm: ECDC; 2018. Stockholm, August 2018 ISBN 978-92-9498-264-3 doi 10.2900/914169 Catalogue number TQ-03-18

2018 European Centre for Disease Prevention and Control - Technical Guidance

100. European Union Standards for Tuberculosis Care

European Union Standards for Tuberculosis Care 1 European Union Standards for Tuberculosis Care 2017 update www.ecdc.europa.euWhere to find ECDC publications Newsletter Subscribe to receive a monthly email about the latest ECDC publications or new print publications based on your areas of interest. http://surveys.publications.europa.eu/formserver/ecdc/subscription.html Link accessible from the ECDC website under ‘Newsletter’. Online www.ecdc.europa.eu Print Order printed copies at the online (...) library for EU publications (EU Bookshop): www.publications.europa.eu/bookshop To access directly all ECDC publications on EU Bookshop: www.europa.eu/!xk84gB To contact us: publications@ecdc.europa.eu Paper ISBN 978-92-9498-248-3 doi: 10.2900/307948 TQ-02-18-860-EN-C PDF ISBN 978-92-9498-247-6 doi: 10.2900/308103 TQ-02-18-860-EN-N1 Introduction 2 Standards for tuberculosis diagnosis 4 Standards for tuberculosis treatment 6 Standards for addressing HIV infection and comorbidities 10 Standards

Full Text available with Trip Pro

2018 European Centre for Disease Prevention and Control - Public Health Guidance